Inhaled human insulin ((insulin human [rDNA origin]) Inhalation Powder) in diabetes mellitus

Expert Opinion on Drug Metabolism and Toxicology

Volumn 2, Issue 5, 2006, Pages 779-791

  Mathieu, Chantal ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Efficacy; Inhaled insulin; Pharmacokinetics; Safety; Type 1 diabetes; Type 2 diabetes

Indexed keywords

HUMAN INSULIN; METFORMIN; RIBOSOME DNA; SULFONYLUREA;

COUGHING; DIABETES MELLITUS; DRUG DOSAGE FORM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; OUTCOME ASSESSMENT; QUALITY OF LIFE; REVIEW;

ADMINISTRATION, INHALATION; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DNA, RIBOSOMAL; FORCED EXPIRATORY VOLUME; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; POWDERS;

EID: 33846291435     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2.5.779     Document Type: Review

References (62)

1. 1c with cardiovascular disease and mortality in adults: the European Prospective Investigation into Cancer in Norfolk. Ann. Intern. Med. (2004) 141:413-420.
2. DIABETES CONTROL AND COMPLICATIONS TRIAL (DCCT) GROUP: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med. (1993) 329:977-986.
3. UNITED KINGDOM PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet (1998) 352:837-853.
4. NATHAN DN, CLEARY PA, BACKLUND JY et al.: Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. N. Engl. J. Med. (2005) 353:2643-2653.
5. STRATTON IM, ADLER AI, NEIL HAW et al.: Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. BMJ (2000) 321:405-412.
6. AMERICAN DIABETES ASSOCIATION: Consensus Development Conference on the diagnosis of coronary heart disease in people with diabetes. 10-11 February 1998, Miami, Florida. Diabetes Care (1998) 21:1551-1559.
7. CAMPBELL IW: Need for intensive, early glycaemic control in patients with Type 2 diabetes. Br. J. Cardiol. (2000) 7:625-631.
8. KENDALL DM, KIM D, MAGGS D: Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of the emerging therapies for Type 2 diabetes. Diabetes Technol. Ther. (2006) 8:385-396.
9. KORYTKOWSKI M: When oral agents fail: practical barriers to starting insulin. Int. J. Obes. (2002) 26(Suppl. 3):S18-S24.
10. FUNNELL MM: Self-management support for insulin therapy in Type 2 diabetes. Diabetes Educator (2004) 30:274-280.
11. HEINEMANN L: Overcoming obstacles: new management options. Eur. J. Endocrinol. (2004) 151:T23-T27.
12. HAYWARD RA, MANNING WG, KAPLAN SH, WAGNER EH, GREENFIELD S: Starting insulin therapy in patients with Type 2 diabetes: effectiveness, complications, and resource utilization. JAMA (1997) 278:1663-1669.
13. NATHAN DM: Clinical practice. Initial management of glycemia in Type 2 diabetes mellitus. N. Engl. J. Med. (2002) 347:1342-1349.
14. RIDDLE MC: The underuse of insulin therapy in North America. Diabetes Metab. Res. Rev. (2002) 18(Suppl. 3):S42-S49.
15. DEL PRATO S, FELTON A-M, MUNRO N et al.: Improving glucose management: ten steps to get more patients with Type 2 diabetes to glycaemic goal. Int. J. Clin. Pract. (2005) 59:1345-1355.
16. TURTLE JR: The economic burden of insulin resistance. Int. J. Clin. Pract. (2000) 113(Suppl.):23-28.
17. OWENS DR, ZINMAN B, BOLLI G: Alternative routes of insulin delivery. Diabetic Med. (2003) 20:886-898.
18. PATTON JS, BUKAR JG, ELDON MA: Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin. Pharmacokinet. (2004) 43:781-801.
19. EXUBERA® [US package insert). Pfizer Laboratories, a division of Pfizer Inc., New York, NY, USA (2006).
20. EXUBERA [EU summary of product characteristics). Pfizer Ltd, Kent, UK.
21. HEINEMANN L, STARKE AA, HOHMANN A, BERGER M: Timing between the subcutaneous administration of insulin and consumption of a carbohydrate rich meal. Horm. Metab. Res. (1992) 26(Suppl.):137-139.
22. HEISE T, HEINEMANN L: Rapid and long-acting analogues as an approach to improve insulin therapy: an evidence-based medicine assessment. Curr. Pharm. Des. (2001) 7:1303-1325.
23. RAVE K, BOTT S, HEINEMANN L et al.: Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care (2005) 28:1077-1082.
24. HENRY RR, FOUNTAINE R, WILLAVIZE S, FISHER J, FRYBURG D: Intrasubject variability of Exubera® (inhaled insulin) comparable to subcutaneous regular insulin in patients with Type 2 diabetes. Endocr. Pract. (2005) 11(Suppl. 1):29-29.
25. FOUNTAINE RJ, WILLAVIZE S, FISHER J, SHA S, FRYBURG D: Pharmacologic reproducibility of prandial inhaled human insulin (Exubera®) in subjects with Type 1 diabetes mellitus (TIDM). Diabetes (2006) 55(Suppl. 1):A112. Abstract 470-P.
26. BRAIN JD: Unlocking the opportunity of tight glycaemic control. Inhaled insulin: safety. Diabetes Obes. Metab. (2005) 7(Suppl. 1):S14-S18.
27. HEISE T, BOTT S, TUSEK C et al.: The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin. A prospective randomized pharmacodynamic study. Diabetes Care (2005) 28:2161-2169.
28. SHA S, BECKER RHA, WILLAVIZE SA et al.: The effect of smoking on the absorption of inhaled insulin (Exubera®). Diabetes (2002) 51(Suppl. 2):A538.
29. BECKER RHA, SHA S, FRICK AD, FOUNTAINE RJ: The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. Diabetes Care (2006) 29:277-282.
30. FOUNTAINE R, MILTON A, WEI G et al.: Effect of acute passive cigarette smoke exposure on the single dose pharmacokinetics of inhaled human insulin (Exubera®). Proceedings of the European Respiratory Society Annual Congress. Munich, Germany (2006):250524.
31. FOUNTAINE RJ, MILTON A, WEI G et al.: Effects of albuterol and fluticasone on inhaled human insulin (Exubera®) pharmacokinetics in patients with mild-to-moderate asthma. Diabetes (2006) 55(Suppl. 1):A112. Abstract 469-P.
32. SCHERBAUM WA: Unlocking the opportunity of tight glycaemic control. Inhaled insulin: clinical efficacy. Diabetes Obes. Metab. (2005) 7(Suppl. 1):S9-S13.
33. CEFALU WT, SKYLER JS, KOURIDES IA et al.: Inhaled human insulin treatment in patients with Type 2 diabetes mellitus. Ann. Intern. Med. (2001) 134:203-207.
34. QUATTRIN T, BELANGER A, BOHANNON NJV, SCHWARTZ SL: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with Type 1 diabetes. Results of a 6-month, randomized, comparative trial. Diabetes Care (2004) 27:2622-2627.
35. SKYLER JS, WEINSTOCK RS, RASKIN P et al.: Use of inhaled insulin in a basal/bolus insulin regimen in Type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care (2005) 28:1630-1635.
36. NORWOOD P, DUMAS R, ENGLAND RD, RIESE RJ, TEETER JG: Inhaled insulin (Exubera) achieves tight glycaemic control and is well tolerated in patients with Type 1 diabetes. Diabetologia (2005) 48(Suppl. 1):A30.
37. JOVANOVIC L, KLIOZE S, REIS J, DUGGAN W; for the EXUBERA 1022 STUDY GROUP: Inhaled human insulin (Exubera®) therapy shows sustained efficacy and is well tolerated over a 2-year period in patients with Type 1 diabetes (T1DM). Diabetes (2006) 55(Suppl. 1):A26.
38. DEFRONZO RA, BERGENSTAL RM, CEFALU WT et al.: Efficacy of inhaled insulin in patients with Type 2 diabetes not controlled with diet and exercise. A 12-week, randomized, comparative trial. Diabetes Care (2005) 28:1922-1928.
39. WEISS SR, CHENG S-L, KOURIDES IA, GELFAND RA, LANDSCHULZ WH: Inhaled insulin provides improved glycemic control in patients with Type 2 diabetes mellitus inadequately controlled with oral agents. A randomized controlled trial. Arch. Intern. Med. (2003) 163:2277-2282.
40. ROSENSTOCK J, ZINMAN B, MURPHY LJ et al.: Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in Type 2 diabetes. A randomized controlled trial. Ann. Intern. Med. (2005) 143:549-558.
41. BARNETT AH, DREYER M, LANGE P, SERDAREVIC-PEHAR M; on behalf of the EXUBERA® PHASE III STUDY GROUP: An open, randomized, parallel group study to compare the efficacy and safety profile of inhaled human insulin (Exubera®) with metformin as adjunctive therapy in patients with Type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care (2006) 29:1282-1287.
42. BARNETT AH, DREYER M, LANGE P, SERDAREVIC-PEHAR M; on behalf of the EXUBERA® PHASE III STUDY GROUP. An open, randomized, parallel group study to compare the efficacy and safety profile of inhaled human insulin (Exubera®) with glibenclamide as adjunctive therapy in patients with Type 2 diabetes poorly controlled on metformin. Diabetes Care (2006) 29:1818-1825.
43. HOLLANDER PA, BLONDE L, ROWE R et al.: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with Type 2 diabetes. Results of a 6-month, randomized, comparative trial. Diabetes Care (2004) 27:2356-2362.
44. ROSENSTOCK J, KLIOZE S, FOYT H, OGAWA M, ST AUBIN L, DUGGAN W; for the EXUBERA 1029 STUDY GROUP: Inhaled human insulin (Exubera®) therapy shows sustained efficacy and is well tolerated over a 2-year period in patients with Type 1 diabetes (T1DM). Diabetes (2006) 55(Suppl. 1):A26.
45. ROSENSTOCK J, CAPPELLERI JC, BOLINDER B, GERBER RA: Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with Type 1 or Type 2 diabetes. Diabetes Care (2004) 27:1318-1323.
46. GERBER RA, CAPPELLERI JC, KOURIDES IA, GELFAND RA: Treatment satisfaction with inhaled insulin in patients with Type 1 diabetes: a randomized controlled trial. Diabetes Care (2001) 24:1556-1559.
47. CAPPELLERI JC, CEFALU WT, ROSENSTOCK J, KOURIDES IA, GERBER RA: Treatment satisfaction in Type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin. Ther. (2002) 24:552-564.
48. TESTA MA, TURNER RR, HAYES JF, SCRANTON RE, SIMONSON DC: An international trial of sulfonylurea plus either metformin or Exubera®: impact on quality of life and treatment satisfaction. Diabetologia (2004) 47(Suppl. 1):A5.
49. SIMONSON DC, TURNER RR, HAYES JF, SCRANTON RE, TESTA MA: Improving quality of life in Type 2 diabetes when Exubera® is added after failure on metformin: a multicentre, international trial. Diabetologia (2004) 47(Suppl. 1):A311.
50. SIMONSON DC, HAYES JF, TURNER RR, TESTA MA: Treatment satisfaction and preferences in Type 2 diabetes: a randomized trial of oral agents versus inhaled insulin. Diabetes (2001) 50(Suppl. 2).
51. TESTA MA, TURNER RR, HAYES JF, SIMONSON DC: Patient satisfaction and quality of life in Type 1 diabetes: a randomized trial of injectable versus inhaled insulin. Diabetes (2001) 50(Suppl. 2):A45.
52. TESTA MA, TURNER RR, HAYES JF, SIMONSON DC: Patient satisfaction with insulin therapy in Type 2 diabetes: a randomized trial of injectable versus inhaled insulin. Diabetes (2002) 51(Suppl. 2):A135.
53. FREEMANTLE N, BLONDE L, DUHOT D et al.: Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with Type 2 diabetes. Diabetes Care (2005) 28:427-428.
54. SKYLER J: Sustained long-term efficacy and safety of inhaled insulin during 4 years of continuous therapy. Diabetes (2004) 53(Suppl. 2):A115.
55. DREYER M: Efficacy and 2-year pulmonary safety of inhaled insulin as adjunctive therapy with metformin or glibenclamide in Type 2 diabetes patients poorly controlled with oral monotherapy. Diabetologia (2004) 47(Suppl. 1):A44.
56. TEETER JG, RIESE RJ: Dissociation of lung function changes with humoral immunity during inhaled human insulin therapy. Am. J. Respir. Crit Care Med. (2006) 173:1194-1200.
57. FINEBERG SE, GALLOWAY JA, FINEBERG NS, RATHBUN MJ, HUFFERD S: Immunogenicity of recombinant DNA human insulin. Diabetologia (1983) 25:465-469.
58. FINEBERG SE, KAWABATA T, FINCO-KENT D, LIU C, KRASNER A: Antibody response to inhaled insulin in patients with Type 1 or Type 2 diabetes. An analysis of initial Phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J. Clin. Endocrinol. Metab. (2005) 90:3287-3294.
59. RIESE RJ, KRASNER A, ENGLAND RD, TEETER JG: Time course of insulin antibody response during inhaled insulin therapy does not correlate with changes in pulmonary function. Eur. Respir. J. (2005) 26(Suppl. 49):582S.
60. http://www.who.int/diabetes/facts/world_figures/en World Health Organization. Prevalence of Diabetes Worldwide (2006).
61. http://www.nice.org.uk/pdf/NICE_INHERI TEG_guidelines.pdf Management of Type 2 Diabetes (Management of Blood Glucose. National Institute for Health and Clinical Excellence (2002).
62. http://www.fda.gov/ohrms/dockets/ac/cder05.html#EndocrinologicMetabolic Endocrinologic and Metabolic Drugs Advisory Committee. Slides September 8, (2005).